(Reuters) – Sanofi SA <SASY.PA> and GlaxoSmithKline Plc <GSK.L> on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers’s experimental COVID-19 vaccine.
The doses would be manufactured in European countries including France, Belgium, Germany and Italy.
Sanofi is leading the clinical development of the vaccine and expects to launch a pivotal trial by the end of this year.
(This story corrects typographical error in headline to “doses” instead of “does”)
(Reporting By Deena Beasley; editing by Grant McCool)